WO2002102320A3 - Fce fusion proteins for treatment of allergy and asthma - Google Patents

Fce fusion proteins for treatment of allergy and asthma Download PDF

Info

Publication number
WO2002102320A3
WO2002102320A3 PCT/US2002/019448 US0219448W WO02102320A3 WO 2002102320 A3 WO2002102320 A3 WO 2002102320A3 US 0219448 W US0219448 W US 0219448W WO 02102320 A3 WO02102320 A3 WO 02102320A3
Authority
WO
WIPO (PCT)
Prior art keywords
fcη
fcε3
fragment
treatment
fce4
Prior art date
Application number
PCT/US2002/019448
Other languages
French (fr)
Other versions
WO2002102320A2 (en
Inventor
Ling-Ling An
Herren Wu
Michael S C Fung
Original Assignee
Tanox Inc
Ling-Ling An
Herren Wu
Michael S C Fung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc, Ling-Ling An, Herren Wu, Michael S C Fung filed Critical Tanox Inc
Priority to EP02744451A priority Critical patent/EP1478748A4/en
Priority to JP2003504909A priority patent/JP2004537991A/en
Priority to US10/479,326 priority patent/US20040198961A1/en
Priority to CA002455387A priority patent/CA2455387A1/en
Priority to MXPA03011499A priority patent/MXPA03011499A/en
Publication of WO2002102320A2 publication Critical patent/WO2002102320A2/en
Publication of WO2002102320A3 publication Critical patent/WO2002102320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention includes Fcε fragments conjugated with FCη fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCη ; FCε2-Fcε3- Fcη; FCε3-Fcη; and FCε3-Fcε4-FCη , or any derivative or peptide, which has equivalent immunological function. The Fcη fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.
PCT/US2002/019448 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma WO2002102320A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02744451A EP1478748A4 (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma
JP2003504909A JP2004537991A (en) 2001-06-15 2002-06-14 Fcε fusion protein for treating allergy and asthma
US10/479,326 US20040198961A1 (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma
CA002455387A CA2455387A1 (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma
MXPA03011499A MXPA03011499A (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29871001P 2001-06-15 2001-06-15
US60/298,710 2001-06-15

Publications (2)

Publication Number Publication Date
WO2002102320A2 WO2002102320A2 (en) 2002-12-27
WO2002102320A3 true WO2002102320A3 (en) 2004-08-26

Family

ID=23151696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019448 WO2002102320A2 (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma

Country Status (7)

Country Link
US (1) US20040198961A1 (en)
EP (1) EP1478748A4 (en)
JP (1) JP2004537991A (en)
CN (1) CN1541266A (en)
CA (1) CA2455387A1 (en)
MX (1) MXPA03011499A (en)
WO (1) WO2002102320A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
MXPA03010037A (en) * 2001-05-01 2004-06-30 Univ California Fusion molecules and methods for treatment of immune diseases.
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
CN1317304C (en) 2004-03-10 2007-05-23 伍祥贵 Fusion protein, gene encoding same, and expression method and use thereof
CA2566535A1 (en) * 2004-05-20 2006-05-11 St. Mary's Hospital Nhs Trust Ige-retargeting, function-altering molecules (erfam) for treatment of allergic diseases
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
CA2630840A1 (en) * 2005-11-23 2007-05-31 Universitaet Zuerich Allergy treatment by epicutaneous allergen administration
KR20110074850A (en) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
CN101633698B (en) * 2009-08-26 2011-12-21 北京精益泰翔技术发展有限公司 Immune fusion protein and gene encoding same and application thereof
WO2012169741A2 (en) * 2011-06-07 2012-12-13 (주)네오팜 Fcεri-specific human antibody and composition comprising same for treating or diagnosing allergic diseases
WO2015002985A2 (en) * 2013-07-01 2015-01-08 University Of Maryland Fc coupled compositions and methods of their use
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
US8961992B1 (en) * 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
CN110551705A (en) * 2019-09-18 2019-12-10 重庆医科大学 Application of streptococcus pneumoniae protein PepN in resisting allergic asthma
WO2022039547A1 (en) * 2020-08-21 2022-02-24 아주대학교산학협력단 Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (cγ1) and epsilon constant region (cε2-4) are fused, and use thereof
CN116410327A (en) * 2021-12-31 2023-07-11 祝道成 Fusion protein and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1999062550A1 (en) * 1998-06-04 1999-12-09 Michael Caplan Pan-specific anti-allergy therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
MXPA03010037A (en) * 2001-05-01 2004-06-30 Univ California Fusion molecules and methods for treatment of immune diseases.
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1999062550A1 (en) * 1998-06-04 1999-12-09 Michael Caplan Pan-specific anti-allergy therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARGOS ET AL.: "An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion", J. MOL. BIOL., vol. 211, February 1990 (1990-02-01), pages 943 - 945, XP009043079 *
BASU ET AL: "Purification and characterization of human recombinant IgE-Fc fragments that bind to the human high affinity IgE receptor", J. BIOL. CHEM., vol. 268, no. 18, 25 June 1993 (1993-06-25), pages 13118 - 13127, XP002978022 *
NISSIM ET AL: "Mapping of the high affinity for Fcepsilon receptor binding site to the third constant region domain of IgE", EMBO JOURNAL, vol. 10, no. 1, January 1991 (1991-01-01), pages 101 - 107, XP002991951 *
See also references of EP1478748A4 *

Also Published As

Publication number Publication date
MXPA03011499A (en) 2004-04-05
EP1478748A4 (en) 2005-09-21
US20040198961A1 (en) 2004-10-07
JP2004537991A (en) 2004-12-24
CA2455387A1 (en) 2002-12-27
EP1478748A2 (en) 2004-11-24
WO2002102320A2 (en) 2002-12-27
CN1541266A (en) 2004-10-27

Similar Documents

Publication Publication Date Title
WO2002102320A3 (en) Fce fusion proteins for treatment of allergy and asthma
US8337844B2 (en) CD20-binding polypeptide compositions for treating autoimmune disease
EP2325209A3 (en) Improved protofibril selective antibodies and the use thereof
WO2002043661A3 (en) Recombinant anti-cd30 antibodies and uses thereof
WO2003042247A3 (en) Modified anti-tnf alpha antibody
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
UY28170A1 (en) PREPARATION AND TREATMENT FOR DEMIELINIZING DISEASES AND PARALYSIS THROUGH THE APPLICATION OF REMIELINIZING AGENTS.
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
MXPA01008612A (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
Brezski et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs
WO2006021954A3 (en) Peptide inhibitors for mediating stress responses
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DE69636527D1 (en) ANTIGENE PROTEIN FROM MALASSEZIA
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
WO2002058728A3 (en) Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
MXPA01008613A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2002034288A8 (en) Vaccine for treating allergy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011499

Country of ref document: MX

Ref document number: 2455387

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003504909

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002344824

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002744451

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028158113

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10479326

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002744451

Country of ref document: EP